PDL BioPharma — Q3 2018 Earnings Presentation
11 slides from PDL BioPharma's earnings presentation, Nov 6, 2018
Slide 1: Third Quarter 2018 Financial Results Conference Call
PDL Third Quarter 2018 Financial Results Conference Call November 6, 2018
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements, including PDL's expectations with respectto its future royalty revenues, expenses, net income, and cash provided by operating activities. Each of these forward-looking statements involves risks and uncertainties. Actua
Slide 3: Assertio (Depomed) Royalties — Amended Agreement
Assertio (Depomed) Royalties — Amended Agreement Q Original agreement: = In October 2013, PDL paid $240.5 million for 100% of royalties and milestones on sales of type 2 diabetes products until cash flows reached $481 million (two times original investment) after which proceeds would be split evenly
Slide 4: Share Repurchase Programs
Share Repurchase Programs a Completed a $25 million program in July 2018 = Since March 2017, we have repurchased 22.1 million shares for a total of $55.0 million. = Average repurchase share price of $2.49. = 146.0 million shares outstanding as of October 30, 2018. a Announced a new $100 million shar
Slide 5: Q3 Increase in Royalty Rights Fair Value Results in Book Value Increase
Q3 18 Increase in Royalty Rights Fair Value Results in a Book Value Increase of $0.22 vs. Prior Quarter PDL’s book value for the period ending September 30, 2018 was $5.07 PDL's Book Value Per Share RSASRSASRSaShSa SSSPREENNNNUWWW REREAD Roa Pyeyspenspeyspepsrerspays asa 4 4 4 4 Ss 5 5 5 6 16 6 6 7
Slide 6: Business Development Strategy Details
@ Business Development Strategy Details Q Pursuing transactions that: = Generate profitable revenue growth; = Deliver attractive risk/reward returns on our invested capital; and « Leverage our expertise in the biopharma space. QO Pursuing the following key categories: = Products or companies that ha
Slide 7: Noden: Focus on Profitability
Noden: Focus on Profitability a Reported revenues on the Noden products for Q318 of $17.8 million. = $9.7 million from U.S. sales and $8.1 million from ROW. a No update on Anchen’s progress in developing a generic aliskiren. a Noden planning an authorized generic version of Tekturna that will allow
Slide 8: LENSAR Update
LENSAR Update a LENSAR reported revenues of $6.6 million in Q3 2018. = 33 percent increase in product revenues over Q3 2017. = 13 percent increase over Q2 2018. a Q3 2018 GAAP net loss of approx. $900,000. » Effectively break-even on an EBITDA basis. Q 7 LENSAR Laser Systems sold in Q3 2018.
Slide 9: Financials
Third Quarter 2018 Financials ‘Three Months Ended Nine Months Ended September 30, September 30, (In thousands, except per share amounts) 2018 2017 2018 2017 Royalties from Queen et al. patents S533 $ 1443 § 4534 § 31,864 Royalty rights - change in fair value 42.184 35,353 66117 132,224 Interest reve
Slide 10: Financials
10 Third Quarter 2018 Financials GAAP net income (loss) attributed to PDL’s shareholders as reported Adjustments Mark-to-market adjustment to fair value assets Non-cash interest revenues Non-cash stock-based compensation expense Non-cash debt offering costs Mark-to-market adjustment on warrants held
Slide 11: Financials
Third Quarter 2018 Financials Condensed consolidated balance sheet (unaudited) Cash, cash equivalents and investments Total notes receivable Royalty rights - at fair value Intangible assets, net Total assets Convertible notes payable Total stockholders's equity September 30, June 30, December 31, 20